RT Journal Article SR Electronic T1 The Contrasting Role of Nasopharyngeal Angiotensin Converting Enzyme 2 (ACE2) Expression in SARS-CoV-2 Infection: A Cross-Sectional Study of People Tested for COVID-19 in British Columbia JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.11.23.20237206 DO 10.1101/2020.11.23.20237206 A1 Nikiforuk, Aidan M. A1 Kuchinski, Kevin S. A1 Twa, David D.W. A1 Lukac, Christine D. A1 Sbihi, Hind A1 Basham, C. Andrew A1 Steidl, Christian A1 Prystajecky, Natalie A. A1 Jassem, Agatha N. A1 Krajden, Mel A1 Patrick, David M A1 Sekirov, Inna YR 2020 UL http://medrxiv.org/content/early/2020/11/27/2020.11.23.20237206.abstract AB Background Angiotensin converting enzyme 2 (ACE2) serves as the host receptor for SARS-CoV-2, with a critical role in viral infection. We aim to understand population level variation of nasopharyngeal ACE2 expression in people tested for COVID-19 and the relationship between ACE2 expression and SARS-CoV-2 viral RNA load, while adjusting for expression of the complementary protease, Transmembrane serine protease 2 (TMPRSS2), soluble ACE2, age, and biological sex.Methods A cross-sectional study of n=424 participants aged 1-104 years referred for COVID-19 testing was performed in British Columbia, Canada. Participants who tested negative or positive for COVID-19 were matched by age and biological sex. Viral and host gene expression was measured by quantitative reverse-transcriptase polymerase chain reaction. Bivariate analysis and multiple linear regression were performed to understand the role of nasopharyngeal ACE2 expression in SARS-CoV-2 infection. The ACE2 gene was targeted to measure expression of transmembrane and soluble transcripts.Findings Analysis shows no association between age and nasopharyngeal ACE2 expression in those who tested negative for COVID-19 (P=0·092). Mean expression of transmembrane (P=1·2e-4), soluble ACE2 (P<0·0001) and TMPRSS2 (P<0·0001) differed between COVID-19-negative and -positive groups. In bivariate analysis of COVID-19-positive participants, expression of transmembrane ACE2 positively correlated with SARS-CoV-2 RNA viral load (P<0·0001), expression of soluble ACE2 negatively correlated (P<0·0001), and no correlation was found with TMPRSS2 (P=0·694). Multivariable analysis showed that the greatest viral RNA loads were observed in participants with high transmembrane ACE2 expression (B=0·886, 95%CI:[0·596 to 1·18]), while expression of soluble ACE2 may protect against high viral RNA load in the upper respiratory tract (B= −0·0990, 95%CI:[−0·176 to −0·0224]).Interpretation Nasopharyngeal ACE2 expression plays a dual, contrasting role in SARS-CoV-2 infection of the upper respiratory tract. Transmembrane ACE2 positively correlates, while soluble ACE2 negatively correlates with viral RNA load after adjusting for age, biological sex and expression of TMPRSS2.Funding This project (COV-55) was funded by Genome British Columbia as part of their COVID-19 rapid response initiative.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project (COV-55) was funded by Genome British Columbia as part of their COVID-19 rapid response initiative. The funder and data stewards played no role in the study design, analysis or interpretation of the results. As such, interpretation of the results does not reflect the views of the funding organization or data stewards. The study was performed as research at the University of British Columbia and British Columbia Centre for Disease Control.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was obtained from the University of British Columbia human ethics board (H20-01110).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the data steward but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the data steward.